A Novel Theranostic Strategy for MMP-14 –Expressing Glioblastomas Impacts Survival

Treatment with CLIO-ICT plus temozolomide increased survival of human GBM-bearing mice by more than 2-fold compared with temozolomide alone.

• Glioblastoma-initiating cells (GICs) are implicated in GBM drug resistance.
• Theranostic nanoparticles specifically targeted GBM tumor cells and GICs, causing toxicity.
• The treatment disrupted tumor blood vessels and induced apoptosis in GICs.
• The nanoparticles allowed for drug tracking using MRI imaging.
• Tumor remission was achieved with the combination treatment, indicating a potential new therapeutic strategy.

AI simplified